Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1999 1
2000 1
2007 1
2008 4
2010 2
2011 5
2012 9
2013 11
2014 12
2015 13
2016 6
2017 8
2018 9
2019 14
2020 9
2021 15
2022 9
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25006120

111 results

Results by year

Filters applied: . Clear all
Page 1
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Döhner H, et al. Blood. 2014 Aug 28;124(9):1426-33. doi: 10.1182/blood-2014-03-560557. Epub 2014 Jul 8. Blood. 2014. PMID: 25006120 Free PMC article. Clinical Trial.
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Wei AH, et al. Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856. Blood. 2020. PMID: 32219442 Free PMC article. Clinical Trial.
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P, Candoni A, Leber B, Sekeres MA, Pollyea DA, Ferdinand R, Ma WW, O'Brien T, O'Connell A, Chan G, Heuser M. Cortes JE, et al. J Hematol Oncol. 2020 Jul 14;13(1):92. doi: 10.1186/s13045-020-00929-8. J Hematol Oncol. 2020. PMID: 32664995 Free PMC article.
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ. Wei AH, et al. J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20. J Clin Oncol. 2019. PMID: 30892988 Free PMC article. Clinical Trial.
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón JA, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G, Cortes JE. Heuser M, et al. Ann Hematol. 2021 May;100(5):1181-1194. doi: 10.1007/s00277-021-04465-4. Epub 2021 Mar 19. Ann Hematol. 2021. PMID: 33740113 Free PMC article. Clinical Trial.
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.
Schliemann C, Gerss J, Wiebe S, Mikesch JH, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel WE, Krug U. Schliemann C, et al. PLoS One. 2016 Oct 7;11(10):e0164499. doi: 10.1371/journal.pone.0164499. eCollection 2016. PLoS One. 2016. PMID: 27716819 Free PMC article. Clinical Trial.
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.
Döhner H, Symeonidis A, Deeren D, Demeter J, Sanz MA, Anagnostopoulos A, Esteve J, Fiedler W, Porkka K, Kim HJ, Lee JH, Usuki K, D'Ardia S, Won Jung C, Salamero O, Horst HA, Recher C, Rousselot P, Sandhu I, Theunissen K, Thol F, Döhner K, Teleanu V, DeAngelo DJ, Naoe T, Sekeres MA, Belsack V, Ge M, Taube T, Ottmann OG. Döhner H, et al. Hemasphere. 2021 Aug 2;5(8):e617. doi: 10.1097/HS9.0000000000000617. eCollection 2021 Aug. Hemasphere. 2021. PMID: 34350385 Free PMC article.
111 results